Patents Represented by Attorney Valeta Gregg, Esq.
  • Patent number: 7635474
    Abstract: Nucleic acid molecules encoding fusion proteins which bind and inhibit vascular endothelial growth factor (VEGF). The VEGF-binding fusion proteins are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.
    Type: Grant
    Filed: June 9, 2008
    Date of Patent: December 22, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Thomas J. Daly, James P. Fandl, Nicholas J. Papadopoulos
  • Patent number: 7632503
    Abstract: A targeting fusion protein comprising a component that comprises a (i) ligand or derivative or fragment thereof that binds a pre-selected target surface protein, such as a receptor, and (ii) an active agent or therapeutic agent(s), and further optionally (iii) a multimerizing component and/or (iv) a signal sequence. In a preferred embodiment, the targeting fusion polypeptide targets muscle and is useful to treat a muscle-related disease or condition, such as muscle atrophy.
    Type: Grant
    Filed: February 14, 2008
    Date of Patent: December 15, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Trevor Stitt, Esther Latres, David J. Glass
  • Patent number: 7615220
    Abstract: An isolated antibody or antibody fragment that binds human interleukin-18 receptor alpha (hIL-18R?), comprising a light chain variable region (LCVR) selected from the group consisting of SEQ ID NO: 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 61, 65, 69, 73, 77, and 81 and/or a heavy chain variable region (HCVR) selected from the group consisting of SEQ ID NO: 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, 51, 55, 59, 63, 67, 71, 75, and 79, or a fragment or sequence modified by an amino acid substitution, deletion or addition thereof.
    Type: Grant
    Filed: April 6, 2007
    Date of Patent: November 10, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Tammy H. Huang, Sean Stevens, Joel H. Martin, Jeanette L. Fairhurst, Kevin J. Pobursky, Margaret Karow, Joan A. Windsor, Warren R. Mikulka
  • Patent number: 7608430
    Abstract: Polypeptides and multimeric polypeptides capable of binding interferon ? which are useful therapeutically in methods of treating interferon ?-related conditions or diseases.
    Type: Grant
    Filed: July 6, 2006
    Date of Patent: October 27, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Margaret Karow, Prerna Sharma
  • Patent number: 7608693
    Abstract: An isolated human antibody or antibody fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4R?) with high affinity (KD), capable of blocking hIL-4 and hIL-13 activity.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: October 27, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Joel H. Martin, Tammy T. Huang, Jeanette L. Fairhurst, Nicholas J. Papadopoulos
  • Patent number: 7608261
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence shown in SEQ ID NO:4.
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: October 27, 2009
    Assignee: Regeneron Pharmacuticals, Inc.
    Inventors: Eric Furfine, Daniel Dix, Kenneth S. Graham, Kelly Frye
  • Patent number: 7557084
    Abstract: Fusion polypeptides and multimeric fusion polypeptides capable of binding interleukin-18 (IL-18) with high affinity, as well as nucleic acids encoding the IL-18-specific polypeptides, which are useful therapeutically in methods of treating IL-18-related conditions or diseases. The IL-18-specific polypeptides may include components derived from IL-18 binding protein (IL-18BP), a fusion component F, an IL-18 receptor, and/or a human interleukin-1 receptor accessory protein (hIL-1RAcP).
    Type: Grant
    Filed: March 31, 2005
    Date of Patent: July 7, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Margaret Karow, Prerna Sharma
  • Patent number: 7524499
    Abstract: Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
    Type: Grant
    Filed: April 14, 2008
    Date of Patent: April 28, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Samuel Davis, George D. Yancopoulos
  • Patent number: 7521049
    Abstract: Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: April 21, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Stanley J. Wiegand, Nicholas J. Papadopoulos, George D. Yancopoulos, James P. Fandl, Thomas J. Daly
  • Patent number: 7482001
    Abstract: A method of treating a human patient suffering from cancer, comprising administering an effective amount of a vascular endothelial growth factor (VEGF) trap antagonist to the human patient, the method comprising: (a) administering to the patient an initial dose of at least approximately 0.3 mg/kg of the VEGF antagonist; and (b) administering to the patient a plurality of subsequent doses of the VEGF antagonist in an amount that is approximately the same or less of the initial dose, wherein the subsequent doses are separated in time from each other by at least one day. The methods of the invention are useful for treating a human cancer selected from the group consisting of renal cell carcinoma, pancreatic carcinoma, breast cancer, prostate cancer, colorectal cancer, malignant mesothelioma, multiple myeloma, ovarian cancer, and melanoma. The invention is further useful for treating a condition which benefits from the reduction of VEGFA and placental growth factor (PLGF).
    Type: Grant
    Filed: February 29, 2008
    Date of Patent: January 27, 2009
    Inventor: Jesse M. Cedarbaum
  • Patent number: 7482002
    Abstract: A method of treating a human patient suffering from cancer, comprising administering an effective amount of a vascular endothelial growth factor (VEGF) trap antagonist to the human patient, the method comprising: (a) administering to the patient an initial dose of at least approximately 0.3 mg/kg of the VEGF antagonist; and (b) administering to the patient a plurality of subsequent doses of the VEGF antagonist in an amount that is approximately the same or less of the initial dose, wherein the subsequent doses are separated in time from each other by at least one day. The methods of the invention are useful for treating a human cancer selected from the group consisting of renal cell carcinoma, pancreatic carcinoma, breast cancer, prostate cancer, colorectal cancer, malignant mesothelioma, multiple myeloma, ovarian cancer, and melanoma. The invention is further useful for treating a condition which benefits from the reduction of VEGFA and placental growth factor (PLGF).
    Type: Grant
    Filed: February 29, 2008
    Date of Patent: January 27, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: Jesse M. Cedarbaum
  • Patent number: 7479274
    Abstract: A method of treating a human patient suffering from cancer, comprising administering an effective amount of a vascular endothelial growth factor (VEGF) trap antagonist to the human patient, the method comprising: (a) administering to the patient an initial dose of at least approximately 0.3 mg/kg of the VEGF antagonist; and (b) administering to the patient a plurality of subsequent doses of the VEGF antagonist in an amount that is approximately the same or less of the initial dose, wherein the subsequent doses are separated in time from each other by at least one day. The methods of the invention are useful for treating a human cancer selected from the group consisting of renal cell carcinoma, pancreatic carcinoma, breast cancer, prostate cancer, colorectal cancer, malignant mesothelioma, multiple myeloma, ovarian cancer, and melanoma. The invention is further useful for treating a condition which benefits from the reduction of VEGFA and placental growth factor (PLGF).
    Type: Grant
    Filed: February 29, 2008
    Date of Patent: January 20, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: Jesse M. Cedarbaum
  • Patent number: 7479273
    Abstract: A method of treating a human patient suffering from cancer, comprising administering an effective amount of a vascular endothelial growth factor (VEGF) trap antagonist to the human patient, the method comprising: (a) administering to the patient an initial dose of at least approximately 0.3 mg/kg of the VEGF antagonist; and (b) administering to the patient a plurality of subsequent doses of the VEGF antagonist in an amount that is approximately the same or less of the initial dose, wherein the subsequent doses are separated in time from each other by at least one day. The methods of the invention are useful for treating a human cancer selected from the group consisting of renal cell carcinoma, pancreatic carcinoma, breast cancer, prostate cancer, colorectal cancer, malignant mesothelioma, multiple myeloma, ovarian cancer, and melanoma. The invention is further useful for treating a condition which benefits from the reduction of VEGFA and placental growth factor (PLGF).
    Type: Grant
    Filed: February 29, 2008
    Date of Patent: January 20, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: Jesse M. Cedarbaum
  • Patent number: 7479275
    Abstract: A method of treating a human patient suffering from cancer, comprising administering an effective amount of a vascular endothelial growth factor (VEGF) trap antagonist to the human patient, the method comprising: (a) administering to the patient an initial dose of at least approximately 0.3 mg/kg of the VEGF antagonist; and (b) administering to the patient a plurality of subsequent doses of the VEGF antagonist in an amount that is approximately the same or less of the initial dose, wherein the subsequent doses are separated in time from each other by at least one day. The methods of the invention are useful for treating a human cancer selected from the group consisting of renal cell carcinoma, pancreatic carcinoma, breast cancer, prostate cancer, colorectal cancer, malignant mesothelioma, multiple myeloma, ovarian cancer, and melanoma. The invention is further useful for treating a condition which benefits from the reduction of VEGFA and placental growth factor (PLGF).
    Type: Grant
    Filed: February 29, 2008
    Date of Patent: January 20, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: Jesse M. Cedarbaum
  • Patent number: 7479272
    Abstract: A method of treating a human patient suffering from cancer, comprising administering an effective amount of a vascular endothelial growth factor (VEGF) trap antagonist to the human patient, the method comprising: (a) administering to the patient an initial dose of at least approximately 0.3 mg/kg of the VEGF antagonist; and (b) administering to the patient a plurality of subsequent doses of the VEGF antagonist in an amount that is approximately the same or less of the initial dose, wherein the subsequent doses are separated in time from each other by at least one day. The methods of the invention are useful for treating a human cancer selected from the group consisting of renal cell carcinoma, pancreatic carcinoma, breast cancer, prostate cancer, colorectal cancer, malignant mesothelioma, multiple myeloma, ovarian cancer, and melanoma. The invention is further useful for treating a condition which benefits from the reduction of VEGFA and placental growth factor (PLGF).
    Type: Grant
    Filed: February 29, 2008
    Date of Patent: January 20, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: Jesse M. Cedarbaum
  • Patent number: 7449182
    Abstract: Disclosed are compositions and methods for treating a disease or condition related to angiogenesis with a vascular endothelial growth factor (VEGF) inhibitor and one or more anti-hypertensive agent(s). The method of the invention is useful for preventing the development of hypertension and/or reducing hypertension in a subject treated with a VEGF inhibitor.
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: November 11, 2008
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jesse M. Cedarbaum, Jocelyn Holash
  • Patent number: 7417134
    Abstract: The present invention provides a fusion polypeptide capable of binding interleukin-1 (O:-1) to form a nonfunctional complex. It also provides a nucleic acid sequence encoding the fusion polypeptide and methods of using the fusion polypeptide.
    Type: Grant
    Filed: May 20, 2005
    Date of Patent: August 26, 2008
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Neil Stahl, George D. Yancopoulos
  • Patent number: 7410781
    Abstract: Polypeptides and multimeric polypeptides capable of binding interleukin-4 (IL-4) and interluekin-13 (IL-13) which are useful therapeutically in methods of treating IL-4 and IL-13-related conditions or diseases.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: August 12, 2008
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Margaret Karow, Jeanette Fairhurst
  • Patent number: 7399612
    Abstract: Nucleic acid molecules encoding fusion proteins which bind and inhibit vascular endothelial growth factor (VEGF). The VEGF-binding fusion proteins are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: July 15, 2008
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Thomas J. Daly, James P. Fandl, Nicholas J. Papadopoulos
  • Patent number: 7396664
    Abstract: Nucleic acid molecules and multimeric proteins capable of binding vascular endothelial growth factor (VEGF). VEGF traps are disclosed which are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.
    Type: Grant
    Filed: August 16, 2005
    Date of Patent: July 8, 2008
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Thomas J. Daly, Nicholas J. Papadopoulos, Margaret Karow